arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TherapeuticsMD, Inc.

TXMD
$2.08 ▲ +0.04 (+1.96%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
65 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

TherapeuticsMD, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth 84.2%
Op. Margin -99.9%
ROIC -2.1%
FCF / Share None
Trailing P/E 208.0x
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 6, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$724.00K
↑ +84.2%
Net Income Profit after all expenses
$95.00K
↑ +115.3%
Operating Margin Operating profit as % of sales
-99.9%
↑ +9.2% 1th
FCF / Share Free cash flow per share
$-0.89
↑ +74.0%
Long-Term Debt Long-term obligations
$93.60M
↑ +3.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
41
Financial Health
6

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 65 quarters